RhumbLine Advisers
PHAT icon

RhumbLine Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

RhumbLine Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Buy
60,346
+4,907
+9% +$56K ﹤0.01% 2580
2026
Q1 		$616K Buy
55,439
+3,346
+6% +$42.3K ﹤0.01% 2480
2025
Q4 		$864K Sell
52,093
-9,620
-16% -$137K ﹤0.01% 2315
2025
Q3 		$726K Sell
61,713
-2,844
-4% -$29.4K ﹤0.01% 2444
2025
Q2 		$619K Buy
64,557
+7,818
+14% +$43.3K ﹤0.01% 2546
2025
Q1 		$356K Buy
56,739
+771
+1% +$4.68K ﹤0.01% 2790
2024
Q4 		$454K Buy
55,968
+5,110
+10% +$63.3K ﹤0.01% 2730
2024
Q3 		$920K Sell
50,858
-4,320
-8% -$60.4K ﹤0.01% 2303
2024
Q2 		$568K Buy
55,178
+8,075
+17% +$83.2K ﹤0.01% 2578
2024
Q1 		$500K Sell
47,103
-1,399
-3% -$11.9K ﹤0.01% 2669
2023
Q4 		$443K Sell
48,502
-8,035
-14% -$69.2K ﹤0.01% 2735
2023
Q3 		$586K Buy
56,537
+6,332
+13% +$86.9K ﹤0.01% 2519
2023
Q2 		$719K Buy
50,205
+17,444
+53% +$201K ﹤0.01% 2470
2023
Q1 		$234K Buy
32,761
+2,029
+7% +$17.8K ﹤0.01% 2700
2022
Q4 		$345K Buy
30,732
+1,805
+6% +$18.6K ﹤0.01% 2618
2022
Q3 		$321K Buy
28,927
+2,278
+9% +$21.7K ﹤0.01% 2699
2022
Q2 		$225K Buy
26,649
+6,681
+33% +$68.7K ﹤0.01% 2889
2022
Q1 		$272K Buy
19,968
+2,761
+16% +$44.6K ﹤0.01% 2671
2021
Q4 		$338K Sell
17,207
-247
-1% -$5.81K ﹤0.01% 2672
2021
Q3 		$560K Buy
17,454
+1,016
+6% +$33.8K ﹤0.01% 2497
2021
Q2 		$556K Buy
16,438
+5,048
+44% +$181K ﹤0.01% 2517
2021
Q1 		$428K Sell
11,390
-810
-7% -$33.9K ﹤0.01% 2561
2020
Q4 		$405K Buy
12,200
+1,280
+12% +$51.9K ﹤0.01% 2526
2020
Q3 		$400K Sell
10,920
-1,870
-15% -$64.8K ﹤0.01% 2388
2020
Q2 		$421K Buy
12,790
+1,367
+12% +$52.5K ﹤0.01% 2424
2020
Q1 		$295K Buy
11,423
+4,437
+64% +$148K ﹤0.01% 2417
2019
Q4 		$218K Buy
+6,986
New +$176K ﹤0.01% 2721

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RhumbLine Advisers's PHAT Position: Q2 2026 in Review

RhumbLine Advisers increased its Phathom Pharmaceuticals (PHAT) stake by 8.9% in Q2 2026, buying an estimated $56K and bringing the position to 60,346 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #2580.

RhumbLine Advisers first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $920K in Q3 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • RhumbLine Advisers held 60,346 shares of Phathom Pharmaceuticals worth $655K as of Q2 2026.
  • RhumbLine Advisers bought 4,907 Phathom Pharmaceuticals shares in Q2 2026, an estimated $56K.
  • Phathom Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2580 holding.
  • RhumbLine Advisers first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • RhumbLine Advisers's Phathom Pharmaceuticals position peaked at $920K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.